Appendix 4D and FY26 Half Year Report
Filed with ASX · · 28 pages · English
Summary by 6ix AI
The report highlights key operational achievements, including FDA clearance for the CT:VQ™ technology and significant growth in SaaS revenue and operational metrics. It also notes a substantial institutional placement to support commercialization efforts and expansion into new markets. The report indicates no dividends were declared during this period, and it includes a qualified auditor's opinion regarding goodwill and intangible assets.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from 4DMedical
- Response to ASX Query Letter
- University of Chicago Medicine adopts CTVQ
- Quarterly Activity Report and Appendix 4C
- 4DMedical Secures US$100+ Million Funding to Accelerate U.S. Expansion and increase Technology Dominance in Software-Based Lung Imaging
- 4DMedical completes $150 million institutional placement
Later from 4DMedical
- S&P DJI Announces March 2026 Quarterly Rebalance
- Update - S&P DJI March 2026 Rebalance of the All Ordinaries
- CTVQ deployed at Mayo Clinic
- CE Mark for CTVQ and $83M placement to fund EU expansion
- 4DMedical receives CE Mark for CT: VQ™, enabling commercial launch across the European Union
Follow 4DMedical into a list and get an email when it puts out news.
Follow 4DMedical